These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1429329)

  • 1. Detection of glycopeptide resistance in clinical isolates of gram-positive bacteria.
    Harding I; Lockett A; Brown E
    J Antimicrob Chemother; 1992 Jul; 30(1):105-8. PubMed ID: 1429329
    [No Abstract]   [Full Text] [Related]  

  • 2. Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against Gram-positive organisms from Europe: 2005-2008.
    Arhin FF; Moeck G; Draghi DC; Pillar CM; Sahm DF
    Int J Antimicrob Agents; 2010 Nov; 36(5):474-6. PubMed ID: 20846829
    [No Abstract]   [Full Text] [Related]  

  • 3. Limitations of presently available glycopeptides in the treatment of Gram-positive infection.
    Ziglam HM; Finch RG
    Clin Microbiol Infect; 2001; 7 Suppl 4():53-65. PubMed ID: 11688535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oritavancin: a new avenue for resistant Gram-positive bacteria.
    Mercier RC; Hrebickova L
    Expert Rev Anti Infect Ther; 2005 Jun; 3(3):325-32. PubMed ID: 15954849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial susceptibility of non-enterococcal intrinsic glycopeptide-resistant Gram-positive organisms.
    Vay C; Cittadini R; Barberis C; Hernán Rodríguez C; Perez Martínez H; Genero F; Famiglietti A
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):183-8. PubMed ID: 17049799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of glycopeptide resistance in clinical isolates of gram-positive bacteria.
    Woodford N; Johnson AP; George RC
    J Antimicrob Chemother; 1991 Oct; 28(4):483-6. PubMed ID: 1761441
    [No Abstract]   [Full Text] [Related]  

  • 7. In vitro activity of oritavancin against Gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2013.
    Karlowsky JA; Walkty AJ; Baxter MR; Adam HJ; Zhanel GG
    Diagn Microbiol Infect Dis; 2014 Dec; 80(4):311-5. PubMed ID: 25294303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycopeptide antibiotic biosynthesis.
    Yim G; Thaker MN; Koteva K; Wright G
    J Antibiot (Tokyo); 2014 Jan; 67(1):31-41. PubMed ID: 24220108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newer glycopeptide antibiotics tested against nosocomial bloodstream isolates.
    Buschelman BJ; Jones RN
    J Antimicrob Chemother; 1993 Mar; 31(3):445-7. PubMed ID: 8486582
    [No Abstract]   [Full Text] [Related]  

  • 10. Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13).
    Mendes RE; Farrell DJ; Sader HS; Flamm RK; Jones RN
    J Antimicrob Chemother; 2015 Feb; 70(2):498-504. PubMed ID: 25362568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Glycopeptide heteroresistance and tolerance in hospital grampositive isolates: "invisible" phenomena to the clinician with clinical implications?].
    Aguilar L; Giménez MJ; Barberán J
    Rev Esp Quimioter; 2009 Dec; 22(4):173-9. PubMed ID: 20082037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates.
    Streit JM; Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2004 Feb; 48(2):137-43. PubMed ID: 14972384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro study to evaluate the sensitivity to daptomycin among gram positive clinical isolates.
    Padmaja K; Umabala P; Prasad KS; Lakshmi V
    Indian J Med Microbiol; 2012; 30(1):114-5. PubMed ID: 22361779
    [No Abstract]   [Full Text] [Related]  

  • 14. In-vitro activity of LY264826, an investigational glycopeptide antibiotic, against gram-positive bloodstream isolates and selected gram-negative bacilli.
    Perl TM; Wenzel RP; Jones RN
    J Antimicrob Chemother; 1992 May; 29(5):596-8. PubMed ID: 1624399
    [No Abstract]   [Full Text] [Related]  

  • 15. Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014.
    Pfaller MA; Sader HS; Flamm RK; Castanheira M; Mendes RE
    Diagn Microbiol Infect Dis; 2018 Jun; 91(2):199-204. PubMed ID: 29567128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycopeptide antibiotic analogs for selective inactivation and two-photon imaging of vancomycin-resistant strains.
    Ariyasu S; Too PC; Mu J; Goh CC; Ding Y; Tnay YL; Yeow EK; Yang L; Ng LG; Chiba S; Xing B
    Chem Commun (Camb); 2016 Mar; 52(25):4667-70. PubMed ID: 26953360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Phenotypic detection of resistance mechanisms in gram-positive bacteria].
    Morosini MI; Cercenado E; Ardanuy C; Torres C
    Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):325-32. PubMed ID: 22130574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vancomycin resistance: are there better glycopeptides coming?
    Linden PK
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):917-28. PubMed ID: 19053904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycopeptide-resistant Gemella haemolysans from blood.
    Reed C; Efstratiou A; Morrison D; Woodford N
    Lancet; 1993 Oct; 342(8876):927-8. PubMed ID: 8105186
    [No Abstract]   [Full Text] [Related]  

  • 20. Genetics of glycopeptide resistance in gram-positive pathogens.
    Courvalin P
    Int J Med Microbiol; 2005 Mar; 294(8):479-86. PubMed ID: 15790292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.